Koda, R T <br/><br/>
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  1999 
 - 489-96 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s002800050928  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--adverse effects<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--adverse effects<br/>Female<br/>Half-Life<br/>Humans<br/>Indoles--adverse effects<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>Thymidylate Synthase--antagonists & inhibitors